Open University of Hong Kong

Top International Academic Institutions Complete Independent Studies Validating C-POLAR™ Technology

Retrieved on: 
Dienstag, Juli 5, 2022
Transport, Czech Academy of Sciences, COVID 19, Staphylococcus aureus, Pseudomonas aeruginosa, Tampere University, Harvard Medical School, COVID, S. aureus, Enterococcus faecalis, Peckham Technology Inc, University, Arrest, GLOBE, Infection, COVID-19, Open University of Hong Kong, Coronavirus, Virus inactivation, Kidney, Overalls, Massachusetts General Hospital, Metropolitan University, Hospital, ASHRAE, Technology, Health, Virus, Solution, Motivation, Escherichia coli, Safety, Czech Republic, Severe acute respiratory syndrome coronavirus 2, Society, University of Minnesota, Vaccine, Pharmaceutical industry, Pseudomonas, Science

The independent studies found that the C-POLAR material was able to eradicate more than 99.9% of pathogens within 5 minutes and is safe for human applications.

Key Points: 
  • The independent studies found that the C-POLAR material was able to eradicate more than 99.9% of pathogens within 5 minutes and is safe for human applications.
  • C-POLAR Technologies is committed to revolutionizing the bioprotection industry with technology that is rooted in significant, validated science, said Steve Gorlin, Chairman of C-POLAR Technologies, Inc.
  • The study found that C-POLAR treated material significantly reduced pathogens viability, with up to 92% reduction in certain pathogens.
  • The companys proprietary technology, C-POLAR material is highly effective and efficient where multiple international studies have shown its ability to arrest, inactivate and eradicate up to 99.9% of viruses and microorganisms.

SOPA Announces 2022 Journalism Awards Finalists

Retrieved on: 
Mittwoch, Mai 11, 2022
Communications, Other Communications, Publishing, COVID-19, Fearless, Google News Lab, GNI, National Temperance Society and Publishing House, Bloomberg News, The New York Times, Senior lecturer, Initium Media, Bloomberg TV Philippines, Semafor, Â, University, SOPA, Taliban, Reuters, South China Morning Post, Journalism, Economist, Philippine Center, The Wall Street Journal, Life, Technology, Radio Free Asia, Open University of Hong Kong, Philippine Center for Investigative Journalism, Film

There are 20 categories, including the new SOPA Awards for Excellence in Audio Reporting and Excellence in Technology Reporting. The investigative reporting category has been renamed as “Carlos Tejada Award for Excellence in Investigative Reporting” to honor the life and work of our late SOPA Editorial Committee member. Carlos, who passed away suddenly late last year, spent more than a decade in Asia, first for The Wall Street Journal, then for The New York Times, directing coverage of some of the biggest stories in the region -- many of which were SOPA Award winners. He joined the committee in 2018.

Key Points: 
  • The Society of Publishers in Asia (SOPA), a Hong Kong-based not-for-profit organization dedicated to pursuing excellence in journalism, today announced the finalists for the SOPA 2022 Awards for Editorial Excellence (full list here ).
  • The annual awards recognizing great journalism in the Asia Pacific region have been given out every year since 1999.
  • This years winners will be announced on June 16 at the virtual SOPA Awards Gala and live-streamed on SOPA Asias YouTube channel from 7pm Hong Kong time.
  • There are 20 categories, including the new SOPA Awards for Excellence in Audio Reporting and Excellence in Technology Reporting.

RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

Retrieved on: 
Montag, April 11, 2022
Private Securities Litigation Reform Act, Cholangiocarcinoma, Diarrhea, Culture, Research, SEC, School, Public health, Vii, Prostate cancer, Nasdaq, Opaganib, Annual report, Gastritis, Pneumonia, Security (finance), Crohn's disease, Population, Helicobacter pylori, Redhill, Marketing, Risk, XE, Delta, Naloxegol, Opioid, Senior, Xi, TNF, Ix, U.S. Securities and Exchange Commission, Genta (company), University, WHO, Forward-looking statement, Mortality, ABC294640, Open University of Hong Kong, National Institute, Severe acute respiratory syndrome coronavirus 2, Gastroenteritis, Review, Feedback, IL-6, Patient, Company, IBS-D, Nature, Cancer, RNA, Immunology, Center, Orphan drug, NTM, MedRxiv, Bronchoalveolar lavage, COVID-19, TEL, Authorization, VP, R, Pharmaceutical industry, Vaccine, Omicron, Infection

TEL AVIV, Israel and RALEIGH, N.C., April 11, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640)1, a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability. Based on the new and previously announced data, opaganib's unique human host-targeted, dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations and remain effective against Omicron sub-variants BA.2, XE and other emerging and future variants.

Key Points: 
  • Opaganib was studied in a global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia (NCT04467840).
  • Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with suggested dual anti-inflammatory and antiviral activity.
  • Opaganib is host-targeted and, based on data accumulated to date, is expected to maintain effect against emerging viral variants, having already shown in vitro inhibition against variants of concern, including Omicron and Delta.
  • All forward-looking statements included in this press release are made only as of the date of this press release.

The Economist GMAT Tutor's $25,000 MBA Scholarship Contest Is Open

Retrieved on: 
Montag, September 16, 2019
Standardized tests, Business education, Education, Ho Man Tin, Open University of Hong Kong, Master of Business Administration, Graduate Management Admission Test, Vocational education

NEW YORK, Sept. 16, 2019 /PRNewswire/ --The Economist's GMAT Tutor Brightest Minds MBA Scholarship Competition launches today.

Key Points: 
  • NEW YORK, Sept. 16, 2019 /PRNewswire/ --The Economist's GMAT Tutor Brightest Minds MBA Scholarship Competition launches today.
  • The annual contest offers a $25,000 scholarship to an array of participating business schools.
  • The contest is open to anyone considering pursuing an MBA or EMBA, all you have to do is take our GMAT simulation test online .
  • The winner may apply their $25,000 scholarship towards tuition at any of the following partnering business schools:
    Lee Shau Kee School of Business and Administration, The Open University of Hong Kong (OUHK)
    The Economist GMAT Tutor is an online GMAT prep course offered by The Economist Group.